How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?

Cellular Signalling

Volumn 24, Issue 8, 2012, Pages 1583-1591

  Jagadeesh, Gowraganahalli ^a   Balakumar, Pitchai ^b   Stockbridge, Norman ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Rajendra Institute of Technology and Sciences   (India)

Author keywords

(Pro)renin receptor; Aliskiren; Cardiovascular renal disorders; PPAR ; Renin angiotensin aldosterone system; Wnt Fz signal transduction

Indexed keywords

ALISKIREN; ALISKIREN PLUS AMLODIPINE; ALISKIREN PLUS AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; ALISKIREN PLUS HYDROCHLOROTHIAZIDE; ALISKIREN PLUS VALSARTAN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CATENIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FRIZZLED PROTEIN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PRORENIN; PRORENIN RECEPTOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; RAMIPRIL; RENIN; STRESS ACTIVATED PROTEIN KINASE; VALSARTAN; WNT PROTEIN;

ALBUMINURIA; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BLOOD VOLUME; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; COUGHING; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY COUGH; ESSENTIAL HYPERTENSION; FOOD DRUG INTERACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY INJURY; LIPID DIET; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC HYPERTENSION;

AMIDES; ANIMALS; CARDIOVASCULAR DISEASES; FUMARATES; HUMANS; KIDNEY DISEASES; SIGNAL TRANSDUCTION;

EID: 84861547441     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2012.04.003     Document Type: Review

References (112)

1. Staessen J.A., Li Y., Richart T. Lancet 2006, 368:1449-1456.
2. Balakumar P., Jagadeesh G. Journal of Cardiovascular Pharmacology 2010, 56:570-579.
3. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., Sraer J.D. The Journal of Clinical Investigation 2002, 109:1417-1427.
4. Nguyen G., Danser A.H. Expert Opinion on Investigational Drugs 2006, 15:1131-1135.
5. Cruciat C.M., Ohkawara B., Acebron S.P., Karaulanov E., Reinhard C., Ingelfinger D., et al. Science 2010, 327:459-463.
6. Balakumar P., Jagadeesh G. Hypertension Research 2011, 34:1161-1170.
7. Advani A., Kelly D.J., Cox A.J., White K.E., Advani S.L., Thai K., et al. Hypertension 2009, 54:261-269.
8. Ferri N., Greco C.M., Maiocchi G., Corsini A. Journal of the Renin-Angiotensin-Aldosterone System 2011, 12:469-474.
9. van Esch J.H., van Veghel R., Garrelds I.M., Leijten F., Bouhuizen A.M., Danser A.H. Hypertension 2011, 57:852-858.
10. Sugawara A., Takeuchi K., Uruno A., Ikeda Y., Arima S., Kudo M., et al. Endocrinology 2001, 142:3125-3134.
11. Hinrichs S., Heger J., Schreckenberg R., Wenzel S., Euler G., Arens C., et al. Cardiovascular Research 2011, 89:344-352.
12. Balakumar P., Kathuria S., Taneja G., Kalra S., Mahadevan N. Journal of Molecular and Cellular Cardiology 2012, 52:83-92.
13. Takada I., Kouzmenko A.P., Kato S. Nature Reviews. Rheumatology 2009, 5:442-447.
14. Danser A.H., van den Dorpel M.A., Deinum J., Derkx F.H., Franken A.A., Peperkamp E., et al. Journal of Clinical Endocrinology and Metabolism 1989, 68:160-167.
15. Danser A.H., Batenburg W.W., van Esch J.H., Krop M. Journal of Molecular Medicine 2008, 86:655-658.
16. Huang Y., Wongamorntham S., Kasting J., McQuillan D., Owens R.T., Yu L., et al. Kidney International 2006, 69:105-113.
17. Saris J.J., 't Hoen P.A., Garrelds I.M., Dekkers D.H., den Dunnen J.T., Lamers J.M., et al. Hypertension 2006, 48:564-571.
18. Matavelli L.C., Huang J., Siragy H.M. Clinical and Experimental Pharmacology and Physiology 2010, 37:277-282.
19. Schefe J.H., Menk M., Reinemund J., Effertz K., Hobbs R.M., Pandolfi P.P., et al. Circulation Research 2006, 99:1355-1366.
20. Derkx F., Schalekamp M. Clinical and Experimental Hypertension. Part A 1988, 10:1213-1225.
21. Wilson D., Leutscher J.A. The New England Journal of Medicine 1990, 323:1101-1106.
22. Deinum J., Ronn B., Mathiesen E., Derkx F.H.M., Hop W.C.J., Schalekamp M.A.D.H. Diabetologia 1999, 42:1006-1010.
23. Nabi A.H.M.N., Uddin M., Nakagawa T., Iwata H., Ichihara A., Inagami T., et al. Frontiers in Bioscience 2007, 12:4810-4817.
24. Ichihara A., Suzuki F., Nakagawa T., Kaneshiro Y., Takemitsu T., Sakoda M., et al. Journal of the American Society of Nephrology 2006, 17:1950-1961.
25. Takahashi H., Ichihara A., Kaneshiro Y., Inomata K., Sakoda M., Takemitsu T., et al. Journal of the American Society of Nephrology 2007, 18:2054-2061.
26. Kaneshiro Y., Ichihara A., Sakoda M., Takemitsu T., Nabi A.H.M.N., Uddin M.N., et al. Journal of the American Society of Nephrology 2007, 18:1789-1795.
27. Muller D.N., Klanke B., Feldt S., Cordasic N., Hartner A., Schmieder R.E., et al. Hypertension 2008, 51:676-681.
28. Feldt S., Maschke U., Dechend R., Luft F.C., Muller D.N. Journal of the American Society of Nephrology 2008, 19:743-748.
29. Sealey J.E., Laragh J.H. American Journal of Hypertension 2009, 22:112-121.
30. Stanton A.V., Dicker P., O'Brien E.T. American Journal of Hypertension 2009, 22:954-957.
31. Sanoski C.A. Pharmacotherapy 2009, 29:193-212.
32. Wood J.M., Maibaum J., Rahuel J., Grütter M.G., Cohen N.C., Rasetti V., et al. Biochemical and Biophysical Research Communications 2003, 308:698-705.
33. TEKTURNA(®) (Aliskiren) Oral Tablets 2007, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/tekturna.pdf. Accessed on 21 Nov, 2011.
34. Pilz B., Shagdarsuren E., Wellner M., Fiebeler A., Dechend R., Gratze P., et al. Hypertension 2005, 46:569-576.
35. Wood J.M., Schnell C.R., Cumin F., Menard J., Webb R.L. Journal of Hypertension 2005, 23:417-426.
36. Oh B.H., Mitchell J., Herron J.R., Chung J., Khan M., Keefe D.L. Journal of the American College of Cardiology 2007, 49:1157-1163.
37. Vaidyanathan S., Jarugula V., Dieterich H.A., Howard D., Dole W.P. Clinical Pharmacokinetics 2008, 47:515-531.
38. Vaidyanathan S., Valencia J., Kemp C., Zhao C., Yeh C.M., Bizot M.N., et al. International Journal of Clinical Practice 2006, 60:1343-1356.
39. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. The New England Journal of Medicine 2008, 358:2433-2446. AVOID Study Investigators.
40. Balakumar P., Chakkarwar V.A., Singh M. Molecular and Cellular Biochemistry 2009, 320:149-162.
41. Imanishi T., Tsujioka H., Ikejima H., Kuroi A., Takarada S., Kitabata H., et al. Hypertension 2008, 52:563-572.
42. Yamamoto E., Kataoka K., Dong Y.F., Nakamura T., Fukuda M., Tokutomi Y., et al. Hypertension 2009, 54:633-638.
43. Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J., Chiang Y., Bedigian M.P. Circulation 2005, 111:1012-1018.
44. Frampton J.E., Curran M.P. Drugs 2007, 67:1767-1792.
45. Pool J.L., Schmieder R.E., Azizi M., Aldigier J.C., Januszewicz A., Zidek W., et al. American Journal of Hypertension 2007, 20:11-20.
46. Andersen K., Weinberger M.H., Egan B., Constance C.M., Ali M.A., Jin J., Keefe D.L. Journal of Hypertension 2008, 26:589-599.
47. Motwani J.G. Journal of the Renin-Angiotensin-Aldosterone System 2002, 3:72-78.
48. Duprez D.A., Munger M.A., Botha J., Keefe D.L., Charney A.N. Journal of Human Hypertension 2010, 24:600-608.
49. Zhu J.R., Sun N.L., Yang K., Hu J., Xu G., Hong H., et al. Hypertension Research 2011, and on behalf of the trial investigators. 10.1038/hr.2011.150.
50. Chrysant S.G., Murray A.V., Hoppe U.C., Dattani D., Patel S., Hsu H., Zhang J. Current Medical Research and Opinion 2008, 24:1039-1047.
51. Drummond W., Sirenko Y.M., Ramos E., Baek I., Keefe D.L. American Journal of Cardiovascular Drugs 2011, 11:327-333.
52. Schmieder R.E., Philipp T., Guerediaga J., Gorostidi M., Bush C., Keefe D.L. Journal of Hypertension 2009, 27:1493-1501.
53. Villamil A., Chrysant S.G., Calhoun D., Schober B., Hsu H., Matrisciano-Dimichino L., Zhang J. Journal of Hypertension 2007, 25:217-226.
54. Baldwin C.M., Plosker G.L. Drugs 2009, 69:833-841.
55. Drummond W., Munger M.A., Rafique Essop M., Maboudian M., Khan M., Keefe D.L. Journal of Clinical Hypertension (Greenwich, Conn.) 2007, 9:742-750.
56. Littlejohn T.W., Trenkwalder P., Hollanders G., Zhao Y., Liao W. Current Medical Research and Opinion 2009, 25:951-959.
57. Brown M.J., McInnes G.T., Papst C.C., Zhang J., MacDonald T.M. Lancet 2011, 377:312-320.
58. Schmieder R.E., Philipp T., Guerediaga J., Gorostidi M., Smith B., Weissbach N., et al. Circulation 2009, 119:417-425.
59. Dietz R., Dechend R., Yu C.M., Bheda M., Ford J., Prescott M.F., Keefe D.L. Journal of the Renin-Angiotensin-Aldosterone System 2008, 9:163-175.
60. Verdecchia P., Calvo C., Möckel V., Keeling L., Satlin A. Blood Pressure 2007, 16:381-391.
61. Palatini P., Jung W., Shlyakhto E., Botha J., Bush C., Keefe D.L. Journal of Human Hypertension 2010, 24:93-103.
62. Andersen K., Weinberger M.H., Constance C.M., Ali M.A., Jin J., Prescott M.F., Keefe D.L. Journal of the Renin-Angiotensin-Aldosterone System 2009, 10:157-167.
63. De Mello W.C., Danser A.H. Hypertension 2000, 35:1183-1188.
64. Whaley-Connell A., Habibi J., Cooper S.A., Demarco V.G., Hayden M.R., Stump C.S., et al. American Journal of Physiology, Endocrinology and Metabolism 2008, 295:E103-E109.
65. Westermann D., Riad A., Lettau O., Roks A., Savvatis K., Becher P.M., et al. Hypertension 2008, 52:1068-1075.
66. Singh V.P., Le B., Khode R., Baker K.M., Kumar R. Diabetes 2008, 57:3297-3306.
67. McMurray J.J., Pitt B., Latini R., Maggioni A.P., Solomon S.D., Keefe D.L., et al. Circulation. Heart Failure 2008, 1:17-24. Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators.
68. Latini R., Masson S., Anand I., Judd D., Maggioni A.P., Chiang Y.T., et al. Circulation 2002, 106:2454-2458. Valsartan Heart Failure Trial Investigators.
69. Solomon S.D., Appelbaum E., Manning W.J., Verma A., Berglund T., Lukashevich V., et al. Circulation 2009, 119:530-537. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators.
70. Krum H., Massie B., Abraham W.T., Dickstein K., Kober L., McMurray J.J., et al. European Journal of Heart Failure 2011, 13:107-114. ATMOSPHERE Investigators.
71. Gheorghiade M., Albaghdadi M., Zannad F., Fonarow G.C., Böhm M., Gimpelewicz C., et al. European Journal of Heart Failure 2011, 13:100-106. ASTRONAUT investigators and study coordinators.
72. Wiggins K.J., Kelly D.J. Kidney International Jul 2009, 76:23-31.
73. Wiecek A., Chudek J., Kokot F. Nephrology, Dialysis, Transplantation 2003, 18:v16-v20.
74. Kelly D.J., Zhang Y., Moe G., Naik G., Gilbert R.E. Diabetologia 2007, 50:2398-2404.
75. Mullins J.J., Peters J., Ganten D. Nature 1990, 344:541-544.
76. Feldman D.L., Jin L., Xuan H., Contrepas A., Zhou Y., Webb R.L., et al. Hypertension 2008, 52:130-136.
77. Siragy H.M., Huang J. Experimental Physiology 2008, 93:709-714.
78. Whaley-Connell A., Nistala R., Habibi J., Hayden M.R., Schneider R.I., Johnson M.S., et al. American Journal of Physiology. Renal Physiology 2010, 298:F655-F661.
79. Fisher N.D., Jan Danser A.H., Nussberger J., Dole W.P., Hollenberg N.K. Circulation 2008, 117:3199-3205.
80. Persson F., Rossing P., Schjoedt K.J., Juhl T., Tarnow L., Stehouwer C.D., et al. Kidney International 2008, 73:1419-1425.
81. Persson F., Lewis J.B., Lewis E.J., Rossing P., Hollenberg N.K., Parving H.H. Clinical Journal of the American Society of Nephrology 2011, 6:1025-1031.
82. Persson F., Lewis J.B., Lewis E.J., Rossing P., Hollenberg N.K., Parving H.H. Journal of the Renin-Angiotensin-Aldosterone System 2011, 10.1177/1470320311417272.
83. Freiberger V., Amann K., Heemann U., Frank H. Transplant International 2009, 22:1110-1113.
84. Neumann J., Ligtenberg G., Klein I.H., Boer P., Oey P.L., Koomans H.A., Blankestijn P.J. Hypertension 2007, 49:506-510.
85. Siddiqi L., Oey P.L., Blankestijn P.J. Nephrology, Dialysis, Transplantation 2011, 26:2930-2934.
86. Morishita Y., Hanawa S., Chinda J., Iimura O., Tsunematsu S., Kusano E. Hypertension Research 2011, 34:308-313.
87. Schefe J.H., Neumann C., Goebel M., Danser J., Kirsch S., Gust R., et al. Journal of Hypertension 2008, 26:1787-1794.
88. Buechling T., Bartscherer K., Ohkawara B., Chaudhary V., Spirohn K., Niehrs C., Boutros M. Current Biology 2010, 20:1263-1268.
89. Hermle T., Saltukoglu D., Grünewald J., Walz G., Simons M. Current Biology 2010, 20:1269-1276.
90. Sivarajah A., McDonald M.C., Thiemermann C. Journal of Pharmacology and Experimental Therapeutics 2005, 313:896-901.
91. Ji Y., Liu J., Wang Z., Liu N., Gou W. Laboratory Investigation 2009, 89:887-902.
92. Balakumar P., Reddy J., Singh M. Molecular and Cellular Biochemistry 2009, 330:187-192.
93. Singh A.P., Singh M., Balakumar P. Journal of Cardiovascular Pharmacology 2008, 51:596-604.
94. Strawn W.B., Ferrario C. Current Opinion in Lipidology 2002, 13:505-512.
95. Balakumar P., Mahadevan N. British Journal of Pharmacology 2012, 165:373-379.
96. Benndorf R.A., Boger R.H. Journal of Hypertension 2008, 26:854-856.
97. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Hypertension 2004, 43:993-1002.
98. Bohm M., Baumhäkel M., Mahfoud F., Werner C. Cardiology 2010, 117:163-173.
99. Verdecchia P., Angeli F., Repaci S., Mazzotta G., Gentile G., Reboldi G. Vascular Health and Risk Management 2009, 5:939-948.
100. Goyal S., Bharti S., Sahoo K.C., Sharma A.K., Arya D.S. Cardiovascular Toxicology 2011, 11:148-156.
101. Zhang G.X., Ohmori K., Nagai Y., Fujisawa Y., Nishiyama A., Abe Y., et al. Journal of Molecular and Cellular Cardiology 2007, 42:804-811.
102. Jalowy A., Schulz R., Heusch G. Journal of the American Society of Nephrology 1999, 11:S129-S136.
103. van de Schans V.A., van den Borne S.W., Strzelecka A.E., Janssen B.J., van der Velden J.L., Langen R.C., et al. Hypertension 2007, 49:473-480.
104. van de Schans V.A., Smits J.F., Blankesteijn W.M. European Journal of Pharmacology 2008, 585:338-345.
105. Yuen C.Y., Wong W.T., Tian X.Y., Wong S.L., Lau C.W., Yu J., et al. Cardiovascular Research 2011, 90:122-129.
106. Polikandriotis J.A., Mazzella L.J., Rupnow H.L., Hart C.M. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25:1810-1816.
107. Oparil S., Yarows S.A., Patel S., Fang H., Zhang J., Satlin A. Lancet 2007, 370:221-229.
108. Nussberger J., Wuerzner G., Jensen C., Brunner H.R. Hypertension 2002, 39:E1-E8.
109. Solomon S.D., Shin S.H., Shah A., Skali H., Desai A., Kober L., et al. European Heart Journal 2011, 32:1227-1234. Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators.
110. Einhorn L.M., Zhan M., Hsu V.D., Walker L.D., Moen M.F., Seliger S.L., et al. Archives of Internal Medicine 2009, 169:1156-1162.
111. Harel Z., Gilbert C., Wald R., Bell C., Perl J., Juurlink D., Beyene J., Shah P.S. BMJ 2012, 344:e42.
112. Novartis Accessed on December 21, 2011. http://www.novartis.com/newsroom/media-releases/en/2011/1572562.shtml.